Cargando…

Potential Clinical Application of Genomics in Multiple Myeloma

Multiple myeloma is a heterogeneous disease with different characteristics, and genetic aberrations play important roles in this heterogeneity. Studies have shown that these genetic aberrations are crucial in prognostication and response assessment; recent efforts have focused on their possible ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soekojo, Cinnie Yentia, de Mel, Sanjay, Ooi, Melissa, Yan, Benedict, Chng, Wee Joo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032230/ https://www.ncbi.nlm.nih.gov/pubmed/29890777 http://dx.doi.org/10.3390/ijms19061721

Ejemplares similares

Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020)

Immunoglobulin M Monoclonal Gammopathies of Clinical Significance
por: Girard, Louis-Pierre, et al.
Publicado: (2022)

Genomic characterization of functional high-risk multiple myeloma patients
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2022)

Natural History and Prognostic Factors at First Relapse in Multiple Myeloma
por: Wang, Chen, et al.
Publicado: (2020)

Immunoglobulin M Paraproteinaemias
por: Girard, Louis-Pierre, et al.
Publicado: (2020)

Fibrillary Glomerulonephritis and Monoclonal Gammopathy: Potential Diagnostic Challenges
por: Da, Yi, et al.
Publicado: (2022)

Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma
por: Jia, Yunlu, et al.
Publicado: (2021)

Stem-cell transplantation in multiple myeloma: how far have we come?
por: Soekojo, Cinnie Y., et al.
Publicado: (2019)

Implications of Heterogeneity in Multiple Myeloma
por: de Mel, Sanjay, et al.
Publicado: (2014)

STAT3: A Promising Therapeutic Target in Multiple Myeloma
por: Chong, Phyllis S. Y., et al.
Publicado: (2019)

Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2019)

Tumor-Associated Macrophages and Related Myelomonocytic Cells in the Tumor Microenvironment of Multiple Myeloma
por: Wang, Samuel S. Y., et al.
Publicado: (2022)

Epicardial and visceral adipose tissue in relation to subclinical atherosclerosis in a Chinese population
por: Ei Ei Khaing, Nang, et al.
Publicado: (2018)

Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence
por: Abid, Muhammad Bilal, et al.
Publicado: (2016)

MMSET: Role and Therapeutic Opportunities in Multiple Myeloma
por: Xie, Zhigang, et al.
Publicado: (2014)

MicroRNA: Important Player in the Pathobiology of Multiple Myeloma
por: Bi, Chonglei, et al.
Publicado: (2014)

Metabolic Vulnerabilities in Multiple Myeloma
por: Lim, Julia S. L., et al.
Publicado: (2022)

Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2019)

CAR T-cell therapy in multiple myeloma: more room for improvement
por: Teoh, Phaik Ju, et al.
Publicado: (2021)

Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2022)

P833: MARCH5 AS A POTENTIAL THERAPEUTIC TARGET IN MULTIPLE MYELOMA
por: Bashiri, Hamed, et al.
Publicado: (2023)

Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma
por: Bi, Chonglei, et al.
Publicado: (2015)

Targeting NF-κB Signaling for Multiple Myeloma
por: Wong, Ada Hang-Heng, et al.
Publicado: (2020)

Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma
por: Xiong, Sinan, et al.
Publicado: (2021)

A Novel Measure of Chromosome Instability Can Account for Prognostic Difference in Multiple Myeloma
por: Chung, Tae-Hoon, et al.
Publicado: (2013)

Epigenetic silencing of long non-coding RNA BM742401 in multiple myeloma: impact on prognosis and myeloma dissemination
por: Li, Zhenhai, et al.
Publicado: (2020)

p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
por: Teoh, P. J., et al.
Publicado: (2014)

Determinants of Sensitivity to DZNep Induced Apoptosis in Multiple Myeloma Cells
por: Xie, Zhigang, et al.
Publicado: (2011)

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
por: Bisht, Kamlesh, et al.
Publicado: (2023)

IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification
por: Teoh, Phaik Ju, et al.
Publicado: (2020)

Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor
por: Lim, Su-Lin, et al.
Publicado: (2020)

Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma
por: Cagnetta, Antonia, et al.
Publicado: (2015)

Clonogenic Multiple Myeloma Cells have Shared stemness Signature Associated with Patient Survival
por: Reghunathan, Renji, et al.
Publicado: (2013)

Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact
por: Li, Zhenhai, et al.
Publicado: (2019)

Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials
por: Chen, Yan‐Ting, et al.
Publicado: (2021)

PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation
por: Teoh, Phaik Ju, et al.
Publicado: (2016)

Plasma Membrane Proteomics Identifies Biomarkers Associated with MMSET Overexpression in T(4;14) Multiple Myeloma
por: Xie, Zhigang, et al.
Publicado: (2013)

The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation
por: de Mel, Sanjay, et al.
Publicado: (2018)

Real‐world utilization and healthcare costs for multiple myeloma: A retrospective analysis of patients in Singapore
por: Bayani, Diana Beatriz, et al.
Publicado: (2023)

Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report
por: Murray, David L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ra5sftm555eoo8s2kdr088c325